Single administration of avelumab induced a complete response in thyroid transcription factor 1‐positive combined Merkel cell carcinoma

Merkel cell carcinoma (MCC) is an aggressive neoplasm and patients with metastasis have poor survival outcomes. Recently, avelumab, an anti‐programmed death ligand 1 (PD‐L1) immune checkpoint inhibitor, was approved for first‐line treatment in patients with metastatic MCC. While the administration i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatology 2020-11, Vol.47 (11), p.1317-1321
Hauptverfasser:	Kanemaru, Hisashi, Fukushima, Satoshi, Mizukami, Yukari, Sawamura, Soichiro, Nakamura, Kayo, Honda, Noritoshi, Makino, Katsunari, Kajihara, Ikko, Aoi, Jun, Makino, Takamitsu, Kawasaki, Takeshi, Kudou, Erina, Jhono, Masayoshi, Ito, Takaaki, Arima, Nobuyuki, Ihn, Hironobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized anti‐programmed death ligand 1 inhibitor Apoptosis avelumab Carcinoma, Merkel Cell - drug therapy Case reports Humans immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy Merkel cell carcinoma Metastases Monoclonal antibodies PD-L1 protein Skin cancer Skin Neoplasms - drug therapy Squamous cell carcinoma Targeted cancer therapy Thyroid gland Thyroid Nuclear Factor 1 Thyroid transcription factor 1 Transcription factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!